Topotecan treatment of adults with primary malignant glioma

Cancer

Volumn 85, Issue 5, 1999, Pages 1160-1165

  Friedman, Henry S ^a   Kerby, Tracy ^a   Fields, Scott ^b   Zilisch, Janice E ^b   Graden, David ^b   McLendon, Roger E ^a   Houghton, Peter J ^c   Arbuck, Susan ^d   Cokgor, Ilkcan ^a   Friedman, Allan H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Brain tumor; Chemotherapy; Glioma; Topotecan

Indexed keywords

TOPOTECAN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; TOPOTECAN; TREATMENT OUTCOME;

EID: 0033041409     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990301)85:5<1160::AID-CNCR21>3.0.CO;2-F     Document Type: Article

References (18)

1. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 1983;52:997-1007.
2. Shapiro WR. Therapy of adult malignant brain tumors: what have the clinical trials taught us? Semin Oncol 1986;13:38-45.
3. Liu LF, D'Arpa P. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance. In: Devita VT Jr., Hellman S, Rosenberg SA, editors. Important advances in oncology. Philadelphia: Lippincott, 1992:79-89.
4. Friedman US, Houghton PJ, Schold SC, Keir S, Bigner DD. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1994;34: 171-4.
5. Sabiers JH, Berger NA, Haaga JR, et al. Phase I trial of topotecan administered as a 72-hour infusion. Proc Am Assoc Cancer Res 1993;34:426.
6. Burris HA, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, et al. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 H continuous infusion. Anticancer Drugs 1994;5:394-402.
7. Garrett MJ, Hughes HJ, Freedman LS. A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma. Clin Oncol 1978;4:71-6.
8. Eagan RT, Childs DS Jr., Layton DD Jr., Laws ER Jr., Bisel HF, Holbrook MA, et al. Dianhydrogalactitol and radiation therapy: treatment of supratentorial glioma. JAMA 1979;241: 2046-50.
9. Solero CL, Monfardini S, Brambilla C, Vaghi A, Valagussa P, Morello G, et al. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials 1979;2:43-8.
10. Walker MD, Green SB, Byar DP, Alexander E Jr., Batzdorf U, Brooks WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N Engl J Med 1980;303:1323-9.
11. Green SB, Byar DP, Walker MD, Pistemaa DA, Alexander E Jr., Batzdorf U, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983;67:121-32.
12. Levin VA, Wara WM, Davis RL, Silver P, Resser KJ, Yatsko K, et al. Northern California Oncology Group protocol 6G91: response to treatment with radiation therapy and seven-drug chemotherapy and irradiation for patients with glioblastoma multiforme. Cancer Treat Rep 1986;70:739-43.
13. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990;18:321-4.
14. Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, et al. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiation therapy with hydroxyurea for malignant gliomas. J Neurosurg 1985;63:218-23.
15. Fine HA. The basis for current treatment recommendations for malignant gliomas. J Neurooncol 1994;20:111-20.
16. Cairncross G. Topotecan for recurrent malignant glioma: long times to tumor progression may indicate efficacy. J Neurooncol 1996;30:163.
17. Zamboni WC, Gajjar AJ, Heideman RL, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998;4:783-9.
18. Houghton PJ, Cheshire PJ, Hallman JD II, Lutz L, Friedman HS, Danks MK, et al. Efficacy of topoisomerase 1 inhibitors, topotecan and irinotecan administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.